Umemura S, Sakamoto G, Sasano H, Tsuda H, Akiyama F, Kurosumi M, Tokuda Y, Watanabe T, Toi M, Hasegawa T, Osamura R Y
Department of Pathology, Tokai University School of Medicine, Isehara, 259-1193, Japan.
Breast Cancer. 2001;8(4):316-20. doi: 10.1007/BF02967531.
For the treatment of patients with metastatic breast cancer by humanized anti- human epidermal growth factor receptor type 2 (HER2) antibody (trastuzumab), it is important to evaluate HER2 status adequately. "A guideline for HER2 testing" and "HER2 atlas" produced by the "Pathological committee for optimal use of trastuzumab" are introduced in this report. Appropriate evaluations of biological markers are essential for targeting therapy.
对于使用人源化抗人表皮生长因子受体2（HER2）抗体（曲妥珠单抗）治疗转移性乳腺癌患者而言，充分评估HER2状态至关重要。本报告介绍了由“曲妥珠单抗最佳使用病理委员会”制定的《HER2检测指南》和《HER2图谱》。对生物标志物进行恰当评估对于靶向治疗至关重要。
